Keyphrases
Heart Failure
100%
Erythropoiesis
100%
Failure Data
100%
Empagliflozin
100%
Empire
100%
Confidence Interval
50%
Placebo
50%
Heart Failure with Preserved Ejection Fraction (HFpEF)
50%
Type 2 Diabetes Mellitus (T2DM)
33%
Anemia
33%
Chronic Kidney Disease
33%
Left Ventricular Ejection Fraction
33%
Patients with Heart Failure
33%
New York Heart Association Class
33%
Iron Metabolism
33%
Erythropoietin
16%
Randomized Placebo-controlled Trial
16%
AIMS™
16%
Once-daily
16%
Hematocrit
16%
Adjusted Means
16%
Diuresis
16%
Hepcidin
16%
Cardioprotection
16%
Baseline Characteristics
16%
Early Effect
16%
Well-balancing
16%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
16%
Hemoconcentration
16%
Treatment-subgroup Interaction
16%
Erythroferrone
16%
Iron Utilization
16%
Medicine and Dentistry
Heart Failure
100%
Erythropoiesis
100%
Empagliflozin
100%
Placebo
66%
Heart Failure with Reduced Ejection Fraction
50%
Maturity Onset Diabetes of the Young
33%
Anemia
33%
Heart Left Ventricle Ejection Fraction
33%
Chronic Kidney Disease
33%
New York Heart Association Class
33%
Iron Metabolism
33%
Symptom
16%
Erythropoietin
16%
Hepcidin
16%
Post-Hoc Analysis
16%
Hematocrit
16%
Diuresis
16%
Sodium Glucose Cotransporter 2 Inhibitor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Empagliflozin
100%
Placebo
66%
Heart Failure with Reduced Ejection Fraction
50%
Non Insulin Dependent Diabetes Mellitus
33%
Chronic Kidney Failure
33%
Anemia
33%
Symptom
16%
Erythropoietin
16%
Hepcidin
16%
Sodium Glucose Cotransporter 2 Inhibitor
16%